Stallergenes Greer : 2018 results in line with the recent indications - 2019 guidance a little better than our expectations - Offer at € 37 from Ares - Accept the offer
>EBITDA recovery: results in line - 2018 EBITDA came in at € 40.2m, up 84%. EBITDA clocked in at € 1,521m vs € 1,553m. EBIT was in line with our expectations at € 17.6m (vs € 17.9me) vs -€ 5.4m in 2017. Net profit is now in positive territory at € 12.8m (vs € 11.5me) vs -€ 9.9m in 2017.Guidance better than consensus expectations - At first glance, we would highlight the following:1- EBITDA is in line with the guidance range (€ 40-45m) implied by ...Stallergenes Greer is engaged in providing a comprehensive approach to allergies diseases, offering allergy specialists a range of products from diagnosis to sublingual and subcutaneous allergen immunothreaphy medicines. Co. portfolio comprises of four product categories; Sublingual products include ORALAIR® and STALORAL®; Subcutaneous products include ALUSTAL®, PHOSTAL®, ALYOSTAL ® and ALBEY®, and GREER EXTRACTS®; Veteninary product is a range of USDA-approved bulk extracts for animals suffering from a range of allergies; and Other products offer a variety of diagnostic tools and source materials in useful formulations for allergy specialists and physicians.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.